Title: Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.
Abstract: Vismodegib (Erivedge, Genentech-Roche) is the first in class of Hedgehog pathway inhibitors approved for treatment of metastatic basal cell carcinoma (BCC), or locally advanced BCC that has recurred after surgery or is not amenable to surgery or radiation. Its path to discovery has been unique and traces its origin to corn lilies, sheep, Drosophila flies, and the Hedgehog signaling pathway. J Drugs Dermatol. 2018;17(5):506-508.
Publication Year: 2018
Publication Date: 2018-05-01
Language: en
Type: article
Indexed In: ['pubmed']
Access and Citation
Cited By Count: 4
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot